New bladder cancer drug shows promise in early trial
NCT ID NCT07222488
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called MK-3120 for high-risk non-muscle invasive bladder cancer. After standard tumor removal, 45 participants will receive the drug directly into the bladder. The main goals are to check safety and how well people tolerate it, while also looking at tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-3120 (SKB410), a biologic given directly into the bladder
What this could lead to
If it works, this could offer a new treatment option for people with high-risk bladder cancer that hasn't spread to the muscle.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply broadly. Side effects like bleeding or severe lab abnormalities are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akershus Universitetssykehus ( Site 0091)
RECRUITINGLorenskog, Akershus, 1478, Norway
Contact Phone: •••-•••-••••
-
Ankara University Health Practice and Research Hospitals ( Site 0132)
RECRUITINGAnkara, 06620, Turkey (Türkiye)
Contact Phone: •••-•••-••••
-
CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011)
RECRUITINGQuébec, Quebec, G1J 1Z4, Canada
Contact Phone: •••-•••-••••
-
Carolina Urologic Research Center ( Site 0006)
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
Contact Phone: •••-•••-••••
-
Centro Ricerche Cliniche di Verona ( Site 0072)
RECRUITINGVerona, Veneto, 37134, Italy
Contact Phone: •••-•••-••••
-
European Interbalkan Medical Center ( Site 0051)
RECRUITINGThessaloniki, 570 01, Greece
Contact Phone: •••-•••-••••
-
Gustave Roussy ( Site 0041)
RECRUITINGVillejuif, Val-de-Marne, 94805, France
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 0112)
RECRUITINGMadrid, Madrid, Comunidad de, 28041, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Virgen de la Victoria ( Site 0111)
RECRUITINGMálaga, Andalusia, 29010, Spain
Contact Phone: •••-•••-••••
-
Medizinische Universität Wien ( Site 0021)
RECRUITINGVienna, State of Vienna, 1090, Austria
Contact Phone: •••-•••-••••
-
Michael G Oefelein Clinical Trials ( Site 0005)
RECRUITINGBakersfield, California, 93301, United States
Contact Phone: •••-•••-••••
-
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081)
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact Phone: •••-•••-••••
-
Rabin Medical Center ( Site 0062)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
UZ Gent ( Site 0031)
RECRUITINGGhent, Oost-Vlaanderen, 9000, Belgium
Contact Phone: •••-•••-••••